Students come out of the JIB trained on the absolute cutting-edge equipment, with the specific skill set needed in the industry today.

Cell therapy, gene therapy, and gene editing companies now employ about 4,900 workers across the region. The sector can add as many as 11,274 jobs over the next decade.

Staff trained at the expanded Thomas Jefferson University institute for bioprocessing will use advanced sensors to create digital twin models for enhanced process development

The 40,000-square-foot expansion is being funded in part through a $2 million grant from Pennsylvania's Redevelopment Assistance Capital Program. The grant was "matched and exceeded" by Thomas Jefferson University’s capital management committee.

Thomas Jefferson University’s Jefferson Institute for Bioprocessing (JIB) has received a $2 million grant through the commonwealth’s Redevelopment Assistance Capital Program (RACP) to add nearly 20,000 square feet of additional academic and training space at its Lower Gwynedd (Montgomery County) training and education facility.

“The Jefferson Institute is on the cutting edge of developing advanced manufacturing technologies for next-generation biologics, including vaccines and cell and gene therapies. I have been impressed by their commitment to diversity and inclusion, as well as workforce development, working with local community colleges and employers to prepare students and professionals for the skills they need for the jobs of the future,” said Senator Collett.

Boston Consulting Group (BCG) and Thomas Jefferson University’s Institute for Bioprocessing (JIB) today launched the Digital Demonstrator for Innovation, a digitally immersive experience that helps executives understand how Industry 4.0 technologies can drive value throughout biopharma operations. 

Philly native is first African-American student accepted into Thomas Jefferson University’s biopharmaceutical engineering master’s program